The decision to escalate treatment for people with highly active axial spondyloarthritis (axSpA) is mainly driven by the physician’s perspective on disease activity, a real-world study has revealed. Further research is needed to better understand these decisions and to optimize axSpA management, according to researchers in the study “…
An experimental therapy called LNK01001 can safely lower a measure of inflammation, pain, and stiffness in adults with active ankylosing spondylitis (AS) who were refractory or intolerant to non-steroidal anti-inflammatory drugs. These top-line data from a 12-week Phase 2 clinical trial support moving LNK01001 to a Phase 3 trial,…
Ankylosing spondylitis (AS) patients undergoing total hip replacement face longer hospital stays and higher related costs than other patients after the surgery, according to an analysis of hospital records. More complications, including anemia and infections, soon after surgery drove these increases in stays and admission-related costs, researchers noted. These…
People with ankylosing spondylitis (AS) are at a significantly higher risk of stroke — a 56% greater risk — than those without this disease, according to a pooled analysis of 11 published studies involving more than 1.7 million participants. Management of stroke risk factors and control of systemic (bodywide)…
The ratio of two blood proteins, fibrinogen and albumin, accurately measures inflammation severity with different types of spondyloarthritis (SpA), including ankylosing spondylitis (AS), a study showed. The accuracy of this biomarker closely matched those of standard inflammatory markers used in research and clinical practice. Further studies are needed to…
Some immune T-cells that react to microbial proteins also target normal human proteins in people who carry HLA-B27 variants, the strongest genetic risk factor contributing to ankylosing spondylitis (AS), a study revealed. The shape of the protein fragments targeted by the immune T-cells, whether human or bacterial, was almost…
One year of UCB Biopharm‘s investigational therapy bimekizumab, administered subcutaneously (under the skin) once every four weeks, resulted in sustained improvement in the signs and symptoms of axial spondyloarthritis (axSpA), according to late-breaking data from two BE MOBILE Phase 3 clinical trials. axSpA is a type of inflammatory…
People with ankylosing spondylitis (AS) who experience uveitis, an inflammatory condition of the eye, have a significantly higher risk of stroke than those without this AS symptom, according to a large medical database analysis. Uveitis in AS also was linked with an increased incidence of known stroke…
Almost all people with axial spondyloarthritis (axSpA) who had worsening disease severity after stopping Taltz (ixekizumab) saw improvements after restarting the therapy, according to data from a Phase 3 withdrawal study. The majority (71%) reached a state of disease remission after restarting treatment. These findings provide important information about…
The European Medicines Agency has agreed to review UCB’s applications seeking the approval of bimekizumab for adults with active axial spondyloarthritis (axSpA). Axial spondyloarthritis is a type of inflammatory arthritis affecting the joints of the spine, chest, and pelvis. Ankylosing spondylitis (AS) is a severe type of axSpA,…
Get regular updates to your inbox.